Cargando…
Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population
INTRODUCTION: The fluocinolone acetonide (FA) intravitreal implant 0.59 mg (Retisert(®), Bausch + Lomb, Rochester, NY, USA) provides sustained release of FA directly to the vitreous cavity over a prolonged period of time. The purpose of this study was to evaluate the safety and efficacy of a 0.59- a...
Autores principales: | Sangwan, Virender S., Pearson, P. Andrew, Paul, Hemanth, Comstock, Timothy L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470982/ https://www.ncbi.nlm.nih.gov/pubmed/25502122 http://dx.doi.org/10.1007/s40123-014-0027-6 |
Ejemplares similares
-
Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant
por: Sheppard, John D, et al.
Publicado: (2012) -
Comment on: “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population”
por: Hall, John
Publicado: (2015) -
The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India
por: Biswas, Jyotirmay, et al.
Publicado: (2023) -
Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis
por: Allen, Rebekah C., et al.
Publicado: (2012) -
Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
por: Park, Jong G., et al.
Publicado: (2020)